Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Carfilzomib (PR-171): Irreversible Proteasome Inhibitor f...

    2025-12-06

    Carfilzomib (PR-171): Irreversible Proteasome Inhibitor for Cancer Biology

    Executive Summary: Carfilzomib (PR-171) is a potent epoxomicin analog and irreversible proteasome inhibitor, routinely used to dissect proteasome-mediated proteolysis in cancer models (APExBIO). It covalently and selectively inhibits the chymotrypsin-like activity of the 20S proteasome at nanomolar concentrations, resulting in profound accumulation of polyubiquitinated proteins and induction of apoptosis, paraptosis, and ferroptosis (Wang et al., 2025). Carfilzomib demonstrates dose-dependent anti-tumor efficacy in animal models with favorable tolerability at intravenous doses up to 5 mg/kg. Its efficacy is mechanistically linked to persistent endoplasmic reticulum stress (ERS) and unfolded protein response (UPR) activation. Optimal use requires precise handling: it is highly soluble in DMSO (≥35.99 mg/mL) but insoluble in water, and stock solutions should be stored desiccated at -20°C.

    Biological Rationale

    The ubiquitin-proteasome system (UPS) is essential for regulated protein catabolism in eukaryotic cells. The 20S core proteasome contains three main catalytic activities: chymotrypsin-like, caspase-like, and trypsin-like. Dysregulation of proteasomal degradation contributes to oncogenesis by permitting accumulation of defective or pro-survival proteins. Inhibiting proteasome function induces cell cycle arrest, apoptosis, and various non-canonical cell death modalities in tumor cells (Wang et al., 2025).

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with high selectivity for the chymotrypsin-like site. By disrupting proteasomal proteolysis, Carfilzomib increases polyubiquitinated protein burden, causing proteotoxic stress and activating the endoplasmic reticulum stress response. In cancer biology research, this enables detailed study of apoptosis induction, tumor growth suppression, and radiosensitization pathways in multiple myeloma, lymphoma, colorectal adenocarcinoma, and esophageal squamous cell carcinoma (ESCC).

    Mechanism of Action of Carfilzomib (PR-171)

    Carfilzomib (SKU A1933) is an epoxyketone-based analog of epoxomicin. It forms a covalent adduct with the N-terminal threonine of the β5 subunit (chymotrypsin-like site) of the 20S proteasome, resulting in irreversible inhibition (APExBIO).

    • Potency: Carfilzomib exhibits an IC50 of less than 5 nM against the chymotrypsin-like activity (IC50=9 nM in HT-29 cells).
    • Selectivity: The compound selectively inhibits the chymotrypsin-like site, with secondary inhibition of caspase-like and trypsin-like activities, especially in cellular contexts.
    • Proteotoxic Stress: Inhibition leads to rapid accumulation of polyubiquitinated proteins, severe ER stress, and UPR activation.
    • Multi-modal Cell Death: Persistent ER stress via UPR (PERK-eIF2α-ATF4, IRE1-XBP1, ATF6) upregulates CHOP, triggering mitochondrial apoptosis, paraptosis, and ferroptosis (Wang et al., 2025).

    Carfilzomib's mechanistic profile distinguishes it from reversible inhibitors, enabling studies on irreversible blockade of proteasome-mediated proteolysis and cellular recovery dynamics (see comparative mechanistic review; this article offers updated, multi-modal cell death insights beyond previous summaries).

    Evidence & Benchmarks

    • Carfilzomib demonstrates sub-nanomolar potency (IC50<5 nM) against the chymotrypsin-like site of the 20S proteasome in biochemical assays (APExBIO).
    • In HT-29 colorectal adenocarcinoma cells, Carfilzomib achieves an IC50 of 9 nM for inhibition of chymotrypsin-like activity (APExBIO).
    • Combination of Carfilzomib with iodine-125 seed radiation induces apoptosis, paraptosis, and ferroptosis in ESCC models via enhanced ER stress and UPR (Wang et al., 2025, DOI).
    • Carfilzomib promotes mitochondrial apoptosis independently of the p53 pathway, mediated by UPR-CHOP activation (Wang et al., 2025).
    • In mouse xenograft models, Carfilzomib is tolerated up to 5 mg/kg IV, suppressing tumor growth without severe toxicity (Wang et al., 2025).
    • Stock solutions are stable at -20°C under desiccated conditions; long-term storage in solution form is not recommended (APExBIO).
    • Solubility: ≥35.99 mg/mL in DMSO; insoluble in water; moderate solubility in ethanol with warming/ultrasound (APExBIO).

    This article builds upon prior scenario-driven reviews (Optimizing Cancer Research Assays), extending the evidence base with new multi-modal cell death data and mechanistic ER stress insights.

    Applications, Limits & Misconceptions

    Carfilzomib (PR-171) is primarily used in cancer biology research for:

    • Studying proteasome inhibition in cancer models (multiple myeloma, lymphoma, colorectal, esophageal cancers).
    • Dissecting apoptosis induction via proteasome inhibition (notably, UPR-mediated mitochondrial apoptosis).
    • Exploring radiosensitization and synergistic cell death in combination with ionizing radiation (Wang et al., 2025).
    • Assaying multi-modal cell death: apoptosis, paraptosis, and ferroptosis.
    • Benchmarking irreversible proteasome inhibition for translational and preclinical oncology studies.

    Common Pitfalls or Misconceptions

    • Misconception 1: Carfilzomib is effective in non-cancerous cell models. Fact: Its cytotoxic effects are context-dependent and are not universal across normal cell types (Wang et al., 2025).
    • Misconception 2: Carfilzomib can be stored long-term in aqueous solution. Fact: It is unstable in solution and requires desiccated storage at -20°C for best results (APExBIO).
    • Misconception 3: Water is a suitable solvent. Fact: Carfilzomib is insoluble in water; use DMSO (≥35.99 mg/mL) or ethanol with warming/ultrasound (APExBIO).
    • Misconception 4: Its effects are exclusively apoptosis-related. Fact: Carfilzomib induces paraptosis and ferroptosis through ER stress as well as apoptosis (Wang et al., 2025).
    • Misconception 5: All proteasome inhibitors act identically. Fact: Carfilzomib is irreversible, with unique selectivity and cellular effects versus reversible inhibitors (contrast: mechanistic review).

    Workflow Integration & Parameters

    For reproducible results, researchers should:

    • Use Carfilzomib (A1933) as supplied by APExBIO (product page).
    • Dissolve in DMSO at concentrations ≥35.99 mg/mL for stock solutions.
    • Store stocks desiccated at -20°C; avoid repeated freeze-thaw cycles.
    • Use ethanol as an alternative solvent only with gentle warming and ultrasonic treatment.
    • Apply dosing regimens in animal studies up to 5 mg/kg IV for tumor xenografts; monitor for toxicity (Wang et al., 2025).
    • Integrate into apoptosis, ER stress, and cell death assays with appropriate controls.

    For troubleshooting and assay optimization, see Carfilzomib (PR-171): Practical Solutions, which discusses real-world assay challenges; this article expands with multi-modal mechanistic updates and latest preclinical benchmarks.

    Conclusion & Outlook

    Carfilzomib (PR-171), as supplied by APExBIO, is a validated tool for dissecting proteasome-mediated proteolysis, apoptosis, and multi-modal cell death in translational cancer research. Peer-reviewed evidence demonstrates its role in potentiating the anti-tumor effects of radiation by aggravating ER stress and activating UPR-dependent cell death pathways (Wang et al., 2025). It remains the reference irreversible proteasome inhibitor for benchmarking and mechanistic study. Future directions include expanded use in radiosensitization studies and in-depth mechanistic dissection of paraptosis and ferroptosis in solid tumors.